1. |
靳建军, 施举红, 陆慰萱, 等. 显微镜下多血管炎肺部病变的临床特点. 中华结核和呼吸杂志, 2011, 34(5): 339-343.
|
2. |
Ando Y, Okada F, Matsumoto S, et al. Thoracic manifestation of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-related disease. CT findings in 51 patients. J Comput Assist Tomogr, 2004, 28(5): 710-716.
|
3. |
Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax, 2008, 63 Suppl 5: v1-58.
|
4. |
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med, 2011, 183(6): 788-824.
|
5. |
Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med, 2005, 172(4): 488-493.
|
6. |
Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J, 2015, 46(4): 976-987.
|
7. |
李学任, 彭守春. 伴有自身免疫特征的间质性肺疾病单中心研究. 中国呼吸与危重监护杂志, 2016, 15(2): 153-157.
|
8. |
陈露露, 张德平, 苗立云. 合并肺部损害的显微镜下多血管炎的临床特征及与特发性肺纤维化的比较分析. 中国呼吸与危重监护杂志, 2011, 10(5): 437-441.
|
9. |
Tanaka T, Otani K, Egashira R, et al. Interstitial pneumonia associated with MPO-ANCA: clinicopathological features of nine patients. Respir Med, 2012, 106(12): 1765-1770.
|
10. |
蔡后荣. 2011 年特发性肺纤维化诊断和治疗循证新指南解读. 中国呼吸与危重监护杂志, 2011, 10(4): 313-316.
|
11. |
Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med, 2015, 192(2): e3-e19.
|
12. |
曹孟淑, 蔡后荣, 代华平. 2015ATS/ERS/JRS/ALAT 官方的临床实践指南: 特发性肺纤维化的治疗 (执行摘要)—对2011年临床指南的更新. 中国呼吸与危重监护杂志, 2016, 15(2): 189-197.
|
13. |
中华医学会呼吸病学分会间质性肺疾病学组. 特发性肺纤维化诊断和治疗中国专家共识. 中华结核和呼吸杂志, 2016, 39(6): 427-432.
|
14. |
Miura Y, Saito T, Fujita K, et al. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis, 2014, 31(3): 235-238.
|
15. |
Udwadia ZF, Mullerpattan JB, Balakrishnan C, et al. Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. Lung India, 2015, 32(1): 50-52.
|